

### REMARKS

Claims 1 – 15 and 17 – 21 are currently pending. In a Notice of Allowance mailed August 9, 2007, claims 1 – 15 and 17 – 21 are allowed. Applicants request continued examination for the purpose of submitting an amendment and Supplemental Information Disclosure Statement. The reference cited in the enclosed IDS, WO 00/66603, was cited in the International Search Report for International Application No. PCT/HR2003/000058. The International Search Report was submitted with the filing of the present application. U.S. 6,872,707, the US patent that issued from WO 00/66603, was disclosed in an IDS submitted October 20, 2005.

Claims 1 – 14, 20 and 21 have been amended in order to place them in a format appropriate to US practice.


It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Dated:

November 8, 2007

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: 919-483-2192  
Fax: 919-483-7988

  
Karen L. Prus

Attorney for Applicant  
Reg. No. 39,337